Merck (MRK) Tops Q4 EPS by 24c

Merck (NYSE: MRK) reported Q4 EPS of $1.80, $0.24 better than the analyst estimate of $1.56. Revenue for the quarter came in at $13.5 billion versus the consensus estimate of $13.46 billion.

GUIDANCE:

Merck sees FY2022 EPS of $7.12-$7.27, versus the consensus of $7.29. Merck sees FY2022 revenue of $56.1-57.6 billion, versus the consensus of $56.64 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
• FDA approves Merck and Eisai kidney cancer combination therapy